The short version of MC4R fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-25. Anything still debated is marked as such rather than presented as settled.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
| Property | Value | Notes |
|---|---|---|
| Storage form | Lyophilized powder | Longer stability at -20 °C |
| Reconstitution solvent | Sterile water or buffer | Depends on intended application |
| Purity assessment | Reverse-phase HPLC | Reported as peak area percentage |
| Identity confirmation | Mass spectrometry | Compared against theoretical mass |
| Main stability concern | Repeated freeze-thaw | May promote aggregation |
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Vortioxetine increases serotonin concentrations in the brain by inhibiting its reuptake in the synapse, and also modulates (activates or blocks) certain serotonin receptors. This puts it in the class of serotonin modulators and stimulators, which also includes vilazodone. More specifically, vortioxetine is a serotonin reuptake inhibitor, agonist of the serotonin 5-HT1A receptor, partial agonist of the 5-HT1B receptor, and antagonist of the serotonin 5-HT1D, 5-HT3, and 5-HT7 receptors, as well as an apparent ligand of the β1-adrenergic receptor. In terms of functional activity however, vortioxetine appears to be much more potent on serotonin reuptake inhibition and 5-HT3 receptor antagonism than for its interactions with the other serotonin receptors. Whereas vortioxetine has IC50 or EC50 values of 5.4 nM for the SERT and 12 nM for the 5-HT3 receptor, its values are 120 to 450 nM for the 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT7 receptors. This translates to about 22- to 83-fold selectivity for SERT inhibition and 10- to 38-fold selectivity for 5-HT3 antagonism over activities at the other serotonin receptors. 5-HT3 antagonism appears to have a better effect on REM sleep compared to paroxetine. The serotonin transporter (SERT) and 5-HT3 receptor are claimed to be primarily occupied at lower clinical doses of vortioxetine and that the 5-HT1B, 5-HT1A, and 5-HT7 receptors may additionally be occupied at higher doses.
Sir Ninian Martin Stephen was selected by Queen Elizabeth II to become the next Governor-General of Australia, to take the place of Sir Zelman Cowen at the latter's retirement in July. Died: Marcel Camus, 69, French film director known for Black Orpheus (Orfeu Negro), winner of the 1959 Palme d'Or and the 1960 Academy Award for Best Foreign Language Film, died following open heart surgery.
== Preparation == Aqueous potassium arsenite, more commonly known as Fowler’s solution, can be prepared by heating arsenic trioxide (As2O3) with potassium hydroxide (KOH) in the presence of water. The reaction is shown below
== External links == MedEd at Loyola grossanatomy/dissector/labs/h_n/pharynx/ph2_1a.html lesson8 at The Anatomy Lesson by Wesley Norman (Georgetown University) (latpharyngealitmes) MedicalMnemonics.com: 669 Cross section at tufts.edu
Sources: en.wikipedia.org
== References == Dean, Adam, and Jonathan Obert. "Rewarded by Friends and Punished by Enemies: The CIO and the Taft-Hartley Act." Labor 18.3 (2021): 78-113. McCann, Irving G. Why the Taft-Hartley Law? New York: Committee for Constitutional Government, 1950. Millis, Harry A. and Brown, Emily Clark. From the Wagner Act to Taft-Hartley: A Study of National Labor Policy and Labor Relations. Chicago: University of Chicago Press, 1950.
== History == For thousands of years, glassmakers were able to make colored glass by adding different dusts and powdered elements such as silver, gold and cadmium and then used different temperatures to produce shades of glass. In the 19th century, scientists started to understand how glass color depended on elements and heating-cooling techniques. It was also found that for the same element and preparation, the color depended on the dust particles' size. Herbert Fröhlich in the 1930s first explored the idea that material properties can depend on the macroscopic dimensions of a small particle due to quantum size effects. The first quantum dots were synthesized in a glass matrix by Alexei A. Onushchenko and Alexey Ekimov in 1981 at the Vavilov State Optical Institute and independently in colloidal suspension by Louis E. Brus team at Bell Labs in 1983. They were first theorized by Alexander Efros in 1982. It was quickly identified that the optical changes that appeared for very small particles were due to quantum mechanical effects. The term quantum dot first appeared in a paper first authored by Mark Reed in 1986. According to Brus, the term "quantum dot" was coined by Daniel S. Chemla while they were working at Bell Labs. In 1993, David J. Norris, Christopher B. Murray and Moungi Bawendi at the Massachusetts Institute of Technology reported on a hot-injection synthesis method for producing reproducible quantum dots with well-defined size and with high optical quality.
On 15 May 2025, during his presidential visit to Qatar, Trump reiterated his desire for the United States to take over the Gaza Strip and "make it a freedom zone". According to "three sources familiar with the effort", Israel and the United States were interested in resettling Gazans to either Syria, Sudan, Morocco, or the separatist Somali regions of Puntland and Somaliland. Somalia and Sudan rejected the proposal, while Puntland and Somaliland expressed willingness to enter discussions on the matter in exchange for diplomatic recognition. In May 2025, reports emerged that the Trump administration was working on a plan to permanently relocate 1 million Gazans to Libya, while offering the release of around $30 billion in funds frozen by the US since the toppling of the regime of Muammar Gaddafi in exchange for Libyan authorities agreeing to the deal. In July, Netanyahu met with Trump and reiterated support for the plan of relocating Palestinians, saying it was "free choice" if Palestinians wanted to stay or leave. The US and Israel were working to identify countries for this plan.
=== Discrimination === People with Hepatitis B in China frequently face discrimination in all aspects of life and work. For example, many Chinese employers and universities refuse to accept anyone who tests positive. Some kindergartens refuse admission to children who are carriers of the virus. The hepatitis problem is a reflection of the vast developmental gap between China's rural and urban areas. The largest problem facing Chinese people infected with HBV is that illegal blood testing is required by most employers in China. According to a report by PBS, faking blood tests by hiring uninfected individuals to take them has become widespread. Following an incident involving a Hepatitis B carrier's killing of an employer and other calls against discriminatory employment practices, China's ministries of health and personnel announced that Hepatitis B carriers must not be discriminated against when seeking employment and education. While the laws exist to protect the privacy of employees and job seekers, many believe that they are not enforced.
== Global statistics == As of 2014, there were 281 marketed orphan drugs and more than 400 orphan-designated drugs in clinical trials. More than 60% of orphan drugs were biologics. The U.S. dominated development of orphan drugs, with more than 300 trials, followed by Europe. Cancer treatment was the indication in more than 30% of orphan drug trials.
Sources: en.wikipedia.org
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.
Reverse-phase HPLC separates components by hydrophobicity and reports purity as a percentage of total peak area. It does not by itself confirm molecular identity. Mass spectrometry is used alongside it for that purpose.
They link a specific lot to its analytical results and storage history. This traceability supports reproducibility when results differ between experiments. Records also help identify when re-testing is warranted.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.